Rhumbline Advisers Sigilon Therapeutics, Inc. Transaction History

Rhumbline Advisers

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.74 - $1.64 $8,292 - $18,377	-11,206 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.24 - $3.03 $342 - $836	276 Added 2.53%	11,206 $16,000
Q4 2021 Feb 10, 2022	BUY	$2.58 - $6.13 $28,199 - $67,000	10,930 New	10,930 $30,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.